|
1. Biologie
|
|
|
|
|
3.1 Tabac
|
|
|
|
5. Traitements
|
|
|
Residual Disease in Oncogene-Driven Solid Tumours [ESMO]
|
|
|
|
|
|
They
propose a shift from the current reactive paradigm of analyzing and
treating acquired drug resistance to a pre-emptive paradigm of defining
the mechanisms that result in residual disease, to target and limit the
residual cells.
|
|
|
|
|
|
|
5.12.3 Immunothérapies-combinaisons
|
|
|
|
5.2.1 Pharma - Partenariats
|
|
|
|
5.2.3 Pharma - économie
|
|
|
|
5.3 Traitements - FDA, EMA,...
|
|
|
|
5.3.4 Traitements - AMM (FDA, EMA)
|
|
|
FDA expands Imbruvica's label to include survival data [Pharma Times]
|
|
|
|
|
|
The
approved label now includes overall survival data from the Phase III
RESONATE-2 trial in treatment-naïve CLL/SLL patients 65 years or older,
which showed a statistically significant 56 percent reduction in the
risk of death in those taking the drug compared to chlorambucil, after a
median follow-up of 28.1 months.
|
|
|
|
|
|
|
6. Lutte contre les cancers
|
|
|
NIH plans overhaul of clinical center leadership [Science]
|
|
|
|
|
|
NIH
now says it will “begin a nationwide search for a physician CEO with
proven experience in management of a complex inpatient and outpatient
facility.” One challenge the agency’s recruitment effort may face is
that salaries at NIH are well below what a hospital CEO would receive in
the private sector.
|
|
|
|
|
|
|
|
6.1 Observation
|
|
|
|
6.10 Politiques
|
|
|
|
|
6.7 DMP, Big Data & applis
|
|
|
|
|
6.8 Communication
|
|
|
|
6.9 Controverses
|
|
|
|
The Imprinter of All Maladies [it is NOT junk]
|
|
|
|
|
|
Biologists
now invoke epigenetics to explain all manner of observations that lie
outside their current ken. Epigenetics pops up frequently among
non-scientists in all manner of discussions about heredity. And all
manner of crackpots slap “epigenetics” on their fringy ideas to give
them a veneer of credibility.
|
|
|
|
|
|